Y-mAbs Therapeutics' Q2 revenue falls 14%

Reuters08-08

Y-mAbs <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' <a href="https://laohu8.com/S/QTWO">Q2</a> revenue falls 14%

Overview

Y-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectations
SERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025
Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19

Outlook

Y-mAbs did not provide further guidance due to pending acquisition
Company to be acquired by SERB Pharmaceuticals by Q4 2025

Result Drivers

U.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competition
EX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern Asia
LICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in Israel

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Product Revenue		$19.50 mln
Q2 EPS	Beat	-$0.07	-$0.27 (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52

Press Release: ID:nGNX47pmBL

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2557523994?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557523994","market":"nz","top_or_hot":-1,"title":"Y-mAbs Therapeutics' Q2 revenue falls 14%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls 14%</title></head><body><p><span>Overview</span></p><ul><li><p>Y-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectations</p></li><li><p>SERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025</p></li><li><p>Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19</p></li></ul><p><span>Outlook</span></p><ul><li><p>Y-mAbs did not provide further guidance due to pending acquisition</p></li><li><p>Company to be acquired by SERB Pharmaceuticals by Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competition</p></li><li><p>EX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern Asia</p></li><li><p>LICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in Israel</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Product Revenue</p></td><td></td><td><p>$19.50 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Beat</p></td><td><p>-$0.07</p></td><td><p>-$0.27 (9 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52</p></li></ul><p>Press Release: <span>ID:nGNX47pmBL</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Y-mAbs Therapeutics' Q2 revenue falls 14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nY-mAbs Therapeutics' Q2 revenue falls 14%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-08 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls 14%</title></head><body><p><span>Overview</span></p><ul><li><p>Y-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectations</p></li><li><p>SERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025</p></li><li><p>Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19</p></li></ul><p><span>Outlook</span></p><ul><li><p>Y-mAbs did not provide further guidance due to pending acquisition</p></li><li><p>Company to be acquired by SERB Pharmaceuticals by Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competition</p></li><li><p>EX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern Asia</p></li><li><p>LICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in Israel</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Product Revenue</p></td><td></td><td><p>$19.50 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Beat</p></td><td><p>-$0.07</p></td><td><p>-$0.27 (9 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52</p></li></ul><p>Press Release: <span>ID:nGNX47pmBL</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YMAB","symbol_name":"Y-mAbs Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nPLX540158:1","article_id":"2557523994","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557523994","pubTimestamp":1754649883,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Y-mAbs Therapeutics' Q2 revenue falls 14%OverviewY-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectationsSERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025Co's acqui","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"YMAB":"Y-mAbs Therapeutics, Inc."},"translate_title":"Y-mAbs Therapeutics第二季度收入下降14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YMAB":0.9},"content_text":"Y-mAbs Therapeutics' Q2 revenue falls 14%OverviewY-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectationsSERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19OutlookY-mAbs did not provide further guidance due to pending acquisitionCompany to be acquired by SERB Pharmaceuticals by Q4 2025Result DriversU.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competitionEX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern AsiaLICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in IsraelKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Product Revenue$19.50 mlnQ2 EPSBeat-$0.07-$0.27 (9 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52Press Release: ID:nGNX47pmBL(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557523994","isCrawlerRequest":true}